Parametric Portfolio Associates LLC lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 4.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 161,933 shares of the biotechnology company’s stock after selling 6,701 shares during the period. Parametric Portfolio Associates LLC owned 0.37% of United Therapeutics Corporation worth $21,008,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in UTHR. BlackRock Inc. boosted its holdings in shares of United Therapeutics Corporation by 3.3% in the 2nd quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock valued at $635,330,000 after buying an additional 155,349 shares during the last quarter. FMR LLC grew its stake in shares of United Therapeutics Corporation by 2.8% in the second quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock valued at $551,980,000 after buying an additional 116,062 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of United Therapeutics Corporation by 0.7% in the second quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock valued at $494,291,000 after buying an additional 25,047 shares in the last quarter. State Street Corp grew its stake in shares of United Therapeutics Corporation by 7.6% in the first quarter. State Street Corp now owns 1,997,327 shares of the biotechnology company’s stock valued at $270,411,000 after buying an additional 140,949 shares in the last quarter. Finally, Palo Alto Investors LLC grew its stake in shares of United Therapeutics Corporation by 0.8% in the first quarter. Palo Alto Investors LLC now owns 1,883,315 shares of the biotechnology company’s stock valued at $254,963,000 after buying an additional 14,500 shares in the last quarter.

ILLEGAL ACTIVITY NOTICE: “United Therapeutics Corporation (UTHR) Holdings Decreased by Parametric Portfolio Associates LLC” was published by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-holdings-decreased-by-parametric-portfolio-associates-llc/1607513.html.

United Therapeutics Corporation (NASDAQ:UTHR) opened at 122.82 on Wednesday. The company has a 50-day moving average of $125.12 and a 200-day moving average of $127.11. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89. The firm has a market cap of $5.34 billion, a price-to-earnings ratio of 14.24 and a beta of 1.49.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of $3.61 by ($4.86). The business had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $4.42 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

Several research firms have issued reports on UTHR. Zacks Investment Research lowered shares of United Therapeutics Corporation from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Jefferies Group LLC reissued a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. ValuEngine raised shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a research report on Monday. BidaskClub lowered shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Finally, UBS AG restated a “sell” rating and set a $106.00 price objective on shares of United Therapeutics Corporation in a research note on Thursday, July 6th. Six research analysts have rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the stock. United Therapeutics Corporation currently has an average rating of “Hold” and a consensus price target of $134.50.

In related news, CEO Martine A. Rothblatt sold 1,265 shares of United Therapeutics Corporation stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $119.70, for a total value of $151,420.50. Following the completion of the sale, the chief executive officer now owns 2,334 shares of the company’s stock, valued at approximately $279,379.80. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,234 shares of United Therapeutics Corporation stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $132.29, for a total value of $163,245.86. Following the completion of the sale, the chief executive officer now directly owns 1,374 shares of the company’s stock, valued at approximately $181,766.46. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,286 shares of company stock valued at $2,338,602. 7.80% of the stock is owned by company insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.